Electrolyte considerations in targeted temperature management
© American Society of Health-System Pharmacists 2022. All rights reserved. For permissions, please e-mail: journals.permissionsoup.com..
PURPOSE: Targeted temperature management (TTM), including normothermia and therapeutic hypothermia, is used primarily for comatose patients with return of spontaneous circulation after cardiac arrest or following neurological injury. Despite the potential benefits of TTM, risks associated with physiological alterations, including electrolyte shifts, may require intervention.
SUMMARY: This review describes the normal physiological balance of electrolytes and temperature-related alterations as well as the impact of derangements on patient outcomes, providing general recommendations for repletion and monitoring of key electrolytes, including potassium, phosphate, and magnesium.
CONCLUSION: Frequent monitoring and consideration of patient variables such as renal function and other risk factors for adverse effects are important areas of awareness for clinicians caring for patients undergoing TTM.
| Medienart: |
E-Artikel |
|---|
| Erscheinungsjahr: |
2023 |
|---|---|
| Erschienen: |
2023 |
| Enthalten in: |
Zur Gesamtaufnahme - volume:80 |
|---|---|
| Enthalten in: |
American journal of health-system pharmacy : AJHP : official journal of the American Society of Health-System Pharmacists - 80(2023), 3 vom: 24. Jan., Seite 102-110 |
| Sprache: |
Englisch |
|---|
| Beteiligte Personen: |
Barlow, Brooke [VerfasserIn] |
|---|
| Links: |
|---|
| Themen: |
Cardiac arrest |
|---|
| Anmerkungen: |
Date Completed 25.01.2023 Date Revised 01.02.2023 published: Print Citation Status MEDLINE |
|---|
| doi: |
10.1093/ajhp/zxac307 |
|---|
| funding: |
|
|---|---|
| Förderinstitution / Projekttitel: |
|
| PPN (Katalog-ID): |
NLM347846165 |
|---|
| LEADER | 01000naa a22002652 4500 | ||
|---|---|---|---|
| 001 | NLM347846165 | ||
| 003 | DE-627 | ||
| 005 | 20231226034812.0 | ||
| 007 | cr uuu---uuuuu | ||
| 008 | 231226s2023 xx |||||o 00| ||eng c | ||
| 024 | 7 | |a 10.1093/ajhp/zxac307 |2 doi | |
| 028 | 5 | 2 | |a pubmed24n1159.xml |
| 035 | |a (DE-627)NLM347846165 | ||
| 035 | |a (NLM)36269999 | ||
| 040 | |a DE-627 |b ger |c DE-627 |e rakwb | ||
| 041 | |a eng | ||
| 100 | 1 | |a Barlow, Brooke |e verfasserin |4 aut | |
| 245 | 1 | 0 | |a Electrolyte considerations in targeted temperature management |
| 264 | 1 | |c 2023 | |
| 336 | |a Text |b txt |2 rdacontent | ||
| 337 | |a ƒaComputermedien |b c |2 rdamedia | ||
| 338 | |a ƒa Online-Ressource |b cr |2 rdacarrier | ||
| 500 | |a Date Completed 25.01.2023 | ||
| 500 | |a Date Revised 01.02.2023 | ||
| 500 | |a published: Print | ||
| 500 | |a Citation Status MEDLINE | ||
| 520 | |a © American Society of Health-System Pharmacists 2022. All rights reserved. For permissions, please e-mail: journals.permissionsoup.com. | ||
| 520 | |a PURPOSE: Targeted temperature management (TTM), including normothermia and therapeutic hypothermia, is used primarily for comatose patients with return of spontaneous circulation after cardiac arrest or following neurological injury. Despite the potential benefits of TTM, risks associated with physiological alterations, including electrolyte shifts, may require intervention | ||
| 520 | |a SUMMARY: This review describes the normal physiological balance of electrolytes and temperature-related alterations as well as the impact of derangements on patient outcomes, providing general recommendations for repletion and monitoring of key electrolytes, including potassium, phosphate, and magnesium | ||
| 520 | |a CONCLUSION: Frequent monitoring and consideration of patient variables such as renal function and other risk factors for adverse effects are important areas of awareness for clinicians caring for patients undergoing TTM | ||
| 650 | 4 | |a Review | |
| 650 | 4 | |a Journal Article | |
| 650 | 4 | |a cardiac arrest | |
| 650 | 4 | |a electrolytes | |
| 650 | 4 | |a hypothermia | |
| 650 | 4 | |a targeted temperature management | |
| 650 | 7 | |a Electrolytes |2 NLM | |
| 650 | 7 | |a Potassium |2 NLM | |
| 650 | 7 | |a RWP5GA015D |2 NLM | |
| 700 | 1 | |a Landolf, Kaitlin |e verfasserin |4 aut | |
| 700 | 1 | |a LaPlante, Reid |e verfasserin |4 aut | |
| 700 | 1 | |a Cercone, Jessica |e verfasserin |4 aut | |
| 700 | 1 | |a Kim, Ji-Yeon |e verfasserin |4 aut | |
| 700 | 1 | |a Ghorashi, Sona |e verfasserin |4 aut | |
| 700 | 1 | |a Howell, Alexandria |e verfasserin |4 aut | |
| 700 | 1 | |a Armahizer, Michael |e verfasserin |4 aut | |
| 700 | 1 | |a Heavner, Mojdeh S |e verfasserin |4 aut | |
| 773 | 0 | 8 | |i Enthalten in |t American journal of health-system pharmacy : AJHP : official journal of the American Society of Health-System Pharmacists |d 1995 |g 80(2023), 3 vom: 24. Jan., Seite 102-110 |w (DE-627)NLM075145952 |x 1535-2900 |7 nnns |
| 773 | 1 | 8 | |g volume:80 |g year:2023 |g number:3 |g day:24 |g month:01 |g pages:102-110 |
| 856 | 4 | 0 | |u http://dx.doi.org/10.1093/ajhp/zxac307 |3 Volltext |
| 912 | |a GBV_USEFLAG_A | ||
| 912 | |a GBV_NLM | ||
| 951 | |a AR | ||
| 952 | |d 80 |j 2023 |e 3 |b 24 |c 01 |h 102-110 | ||